Clinical update at ASCO with new responses in esophagogastric junction (EGJ), lung, and head & neck cancers, and late stage development initiated in EGJ cancer

Read more

Adaptimmune in the context of the COVID-19 pandemic

Learn More

Adaptimmune Announces Q1 2020 Financial Results

Read more

Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the EU for the Treatment of Soft Tissue Sarcoma

Read More

Read our release from ASGCT 2020: SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets

Read More
Our Clinical Trials

Advancing T-cell therapy through world-class expertise

Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.

For Patients and Families

Helpful resources for patients and their families

Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.

View Our Resources
Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.

View Our Pipeline

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.

Learn More